Skip to main content
Premium Trial:

Request an Annual Quote

Ventana Rejects Roche Acquisition Offer Again as Discussions Continue

NEW YORK (GenomeWeb News) – Ventana Medical Systems has urged its shareholders again to reject Roche’s extended offer to buy the firm for $75 per share.
The offer marks the fifth time that Roche has sought to get approval from Ventana’s shareholders to acquire the firm for $75 per share, or roughly $3 billion. Ventana’s stock closed yesterday at $86.07 on the Nasdaq.
Ventana issued a statement last night rejecting Roche’s latest offer, urging its stockholders “not to tender any of their shares to Roche at this inadequate price.” According to the Tucson, Ariz.-based company, less than .2 percent of its approximately 35 million outstanding shares have been tendered pursuant to the offer.
In an effort to get Roche to increase its offer, in November Ventana agreed to let Roche examine its books and gave the diversified Swiss healthcare giant access to non-public information that it believes would provide Roche greater insight into Ventana’s “business prospects and the inherent value in companion diagnostics.”
In the statement last night, Ventana President and CEO Christopher Gleeson said, “Our discussions with Roche under the confidentiality agreement are progressing, and we remain committed to providing superior value to our investors.”
Roche’s latest offer expires at 5:00 PM EST on March 14.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.